Snapshot from Aug 09, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Mission divests MTX652 to Dimerix
Business asset divestment

Mission divests MTX652 to Dimerix

Analysis based on 7 articles · First reported Jul 17, 2026 · Last updated Jul 21, 2026

Sentiment
15
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The deal validates Mission's USP30 platform and provides funding for its CNS pipeline, potentially boosting investor confidence. Dimerix expands its renal pipeline with a Phase 2-ready asset, strengthening its position in kidney disease.

Biotechnology Pharmaceuticals
Event Summary

Paragon Therapeutics, a clinical-stage biotechnology company, announced the divestment of its Phase 2-ready drug candidate MTX652 to Dimerix Limited, an ASX-listed renal specialist. MTX652 is a selective USP30 inhibitor for Acute Kidney Injury (AKI). Under the agreement, Mission will receive up to US$292 million in upfront and milestone payments plus tiered royalties. The deal provides non-dilutive capital for Mission to accelerate its lead CNS program MTX325 for Parkinson's disease. Dimerix will advance MTX652 through clinical development, complementing its Phase 3 FSGS program. Guggenheim Partners acted as financial advisor and Cooley LLP as legal counsel to Mission.

Key Actions
100 Paragon Therapeutics divested Dimerix
100 Dimerix acquired Paragon Therapeutics
80 Paragon Therapeutics received upfront
10 Guggenheim Partners acted as advisor Paragon Therapeutics
10 Cooley LLP acted as counsel Paragon Therapeutics
Entities Involved
priv
Paragon Therapeutics
Divests MTX652 to focus on CNS pipeline, receives up to $292M in payments.
Importance 100.0 Sentiment 40.0
stock
Dimerix
Acquires Phase 2-ready AKI asset, expanding renal pipeline.
Importance 90.0 Sentiment 50.0
per
Anker Lundemose
Executive Director of Mission, announced the deal.
Importance 30.0 Sentiment 0.0
per
Nina Webster
CEO & Managing Director of Dimerix, commented on the acquisition.
Importance 30.0 Sentiment 0.0
priv
Guggenheim Partners
Acted as exclusive financial advisor to Mission.
Importance 10.0 Sentiment 0.0
priv
Cooley LLP
Acted as legal counsel to Mission.
Importance 10.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Approved Phase 2 trial protocol for MTX652.
Importance 10.0 Sentiment 0.0
subs
Pfizer — Pfizer Ventures
Investor in Mission, not directly involved in the deal.
Importance 5.0 Sentiment 0.0
priv
Sofinnova Partners
Investor in Mission.
Importance 5.0 Sentiment 0.0
priv
Roche Venture Fund
Investor in Mission.
Importance 5.0 Sentiment 0.0
priv
SR One
Investor in Mission.
Importance 5.0 Sentiment 0.0
priv
IP Group
Investor in Mission.
Importance 5.0 Sentiment 0.0
priv
Rosetta Capital
Investor in Mission.
Importance 5.0 Sentiment 0.0
curr
United States — United States dollar
Currency of the deal value.
Importance 5.0 Sentiment 0.0
exch
Australian Securities Exchange
Exchange where Dimerix is listed.
Importance 5.0 Sentiment 0.0
Relationships
Paragon Therapeutics related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.